U.S. Serial No. 09/891,064

Docket No. 26068-08D

LISTING OF CLAIMS

1. (Previously presented) An isolated and purified human occuldin polypeptide having at

Examiner: P.Nolan

Art Unit: 1644

least about 60% sequence homology with residues 33 to 522 of SEQ. ID. NO: 2, the

polypeptide being active in inhibiting epithelial or endothelial barriers.

2. (Previously presented) An isolated and purified human occuldin polypeptide having at

least about 80% sequence homology with residues 33 to 522 of SEQ. ID. NO: 2, the

polypeptide being active in inhibiting epithelial or endothelial barriers.

3. (Previously presented) An isolated and purified human occuldin polypeptide having at

least about 90% sequence homology with residues 33 to 522 of SEQ. ID. NO: 2, the

polypeptide being active in inhibiting epithelial or endothelial barriers.

4. - 20. (Cancelled)

21. (Previously presented) A polypeptide according to claim 1 comprising residues 89 to

138 of SEQ. ID. NO: 2.

22. (Previously presented) A polypeptide according to claim 1 comprising residues 196 to 246

2

of SEQ. ID. NO: 2.

{W1271899}

Examiner: P.Nolan Art Unit: 1644

- 23. (Previously presented) A polypeptide according to claim 2 comprising residues 89 to 138 of SEQ. ID. NO: 2.
- 24. (Previously presented) A polypeptide according to claim 2 comprising residues 196 to 246 of SEQ. ID. NO: 2.
- 25. (Previously presented) A polypeptide according to claim 3 comprising residues 89 to 138 of SEQ. ID. NO: 2.
- 26. (Previously presented) A polypeptide according to claim 3 comprising residues 196 to 246 of SEQ. ID. NO: 2.

3

{W1271899}